Robyn Karnauskas
Stock Analyst at Truist Securities
(1.91)
# 3,211
Out of 5,132 analysts
177
Total ratings
43.42%
Success rate
-0.04%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,040.00 | +13.65% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.10 | +222.58% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $369.19 | -19.28% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $60.74 | +7.01% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $121.41 | -9.40% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $154.98 | -46.44% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $231.50 | -9.29% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.25 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $196.52 | +73.01% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.15 | +2,160.87% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.61 | +334.78% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $803.17 | +41.32% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.70 | +488.24% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.55 | +252.94% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $26.45 | -13.04% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $25.75 | +86.41% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $18.92 | +164.27% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $491.47 | +3.36% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.58 | +30.53% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $69.45 | -64.00% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.58 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $59.87 | +133.84% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.12 | +1,414,994.34% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.25 | +460.00% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $20.50 | +168.29% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $8.07 | +3,865.30% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $22.07 | -32.03% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,040.00
Upside: +13.65%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.10
Upside: +222.58%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $369.19
Upside: -19.28%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $60.74
Upside: +7.01%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $121.41
Upside: -9.40%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $154.98
Upside: -46.44%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $231.50
Upside: -9.29%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.25
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $196.52
Upside: +73.01%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.15
Upside: +2,160.87%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.61
Upside: +334.78%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $803.17
Upside: +41.32%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.55
Upside: +252.94%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $26.45
Upside: -13.04%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $25.75
Upside: +86.41%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $18.92
Upside: +164.27%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $491.47
Upside: +3.36%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.58
Upside: +30.53%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $69.45
Upside: -64.00%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.58
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $59.87
Upside: +133.84%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.12
Upside: +1,414,994.34%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.25
Upside: +460.00%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $20.50
Upside: +168.29%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $8.07
Upside: +3,865.30%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $22.07
Upside: -32.03%